Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan’s effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayza, Muluken Altaye, Zewdie, Kaleab Alemayehu, Tesfaye, Bekalu Amare, Gebrekirstos, Selamawit Tesfamariam, Berhe, Derbew Fikadu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567533/
https://www.ncbi.nlm.nih.gov/pubmed/33116714
http://dx.doi.org/10.2147/DMSO.S265399
_version_ 1783596343534551040
author Ayza, Muluken Altaye
Zewdie, Kaleab Alemayehu
Tesfaye, Bekalu Amare
Gebrekirstos, Selamawit Tesfamariam
Berhe, Derbew Fikadu
author_facet Ayza, Muluken Altaye
Zewdie, Kaleab Alemayehu
Tesfaye, Bekalu Amare
Gebrekirstos, Selamawit Tesfamariam
Berhe, Derbew Fikadu
author_sort Ayza, Muluken Altaye
collection PubMed
description Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan’s effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPARγ-agonistic effect while avoiding the safety concerns found with full PPARγ agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPARγ-agonistic activity.
format Online
Article
Text
id pubmed-7567533
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75675332020-10-27 Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity Ayza, Muluken Altaye Zewdie, Kaleab Alemayehu Tesfaye, Bekalu Amare Gebrekirstos, Selamawit Tesfamariam Berhe, Derbew Fikadu Diabetes Metab Syndr Obes Review Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan’s effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPARγ-agonistic effect while avoiding the safety concerns found with full PPARγ agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPARγ-agonistic activity. Dove 2020-10-12 /pmc/articles/PMC7567533/ /pubmed/33116714 http://dx.doi.org/10.2147/DMSO.S265399 Text en © 2020 Ayza et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Ayza, Muluken Altaye
Zewdie, Kaleab Alemayehu
Tesfaye, Bekalu Amare
Gebrekirstos, Selamawit Tesfamariam
Berhe, Derbew Fikadu
Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_full Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_fullStr Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_full_unstemmed Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_short Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
title_sort anti-diabetic effect of telmisartan through its partial pparγ-agonistic activity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567533/
https://www.ncbi.nlm.nih.gov/pubmed/33116714
http://dx.doi.org/10.2147/DMSO.S265399
work_keys_str_mv AT ayzamulukenaltaye antidiabeticeffectoftelmisartanthroughitspartialppargagonisticactivity
AT zewdiekaleabalemayehu antidiabeticeffectoftelmisartanthroughitspartialppargagonisticactivity
AT tesfayebekaluamare antidiabeticeffectoftelmisartanthroughitspartialppargagonisticactivity
AT gebrekirstosselamawittesfamariam antidiabeticeffectoftelmisartanthroughitspartialppargagonisticactivity
AT berhederbewfikadu antidiabeticeffectoftelmisartanthroughitspartialppargagonisticactivity

Ejemplares similares